Abstract:The emerging CRISPR/Cas9 system represents a promising platform for genome editing. However, its low transfection efficiency is a major problem hampering the application of the gene-editing potential of CRISPR/Cas9. Herein, by screening a pool of more than 56 kinds of agents, we constructed a novel polyethylene glycol phospholipid-modified cationic lipid nanoparticle (PLNP)-based delivery system that can condense and encapsulate a Cas9/single-guide RNA (sgRNA) plasmid (DNA) to form a core–shell structure (PLNP/DNA) that mediated up to 47.4% successful transfection of Cas9/sgPLK-1 plasmids in A375 cells in vitro. An intratumor injection of Cas9/sgPLK-1 plasmids into melanoma tumor-bearing mice resulted in significant downregulation of Polo-like kinase 1 (PLK-1) protein and suppression of the tumor growth (>67%) in vivo. This approach provides a versatile method that could be used for delivering the CRISPR/Cas9 system with high efficiency and safety both in vitro and in vivo. A material for delivering CRISPR–Cas9 to the nuclei of cells has been developed by researchers in China. CRISPR–Cas9 is a powerful gene editing system found in bacteria. Scientists have recently harnessed it to edit genes in mammalian cells and even human embryos, opening the door to a host of revolutionary medical treatments. But the plasmid encoding CRISPR–Cas9 is a large nucleic acid, which limits the efficiency with which it can enter target cells. Now, Xingyu Jiang from the National Center for Nanoscience and Technology, Beijing, and colleagues have demonstrated a versatile method for delivering CRISPR–Cas9 efficiently and safely. After screening more than 56 agents, they constructed polyethylene glycol phospholipid–modified cationic lipid nanoparticles to encapsulate CRISPR–Cas9, which allowed nanoparticles to be delivered to melanoma cells with an efficiency of 47%. Our work contributes to synthesize a vehicle based on lipid nanoparticles, which can effectively deliver Cas9/sgRNA-fused plasmid DNA in vitro and in vivo. This approach mediated successful transfection of Cas9/sgRNA plasmids in multiple cell lines in vitro. The vehicle carrying Cas9/sgRNA targeting PLK-1 resulted in significant down-regulation of PLK-1 protein and suppression of melanoma growth in vivo.

The CRISPR-Cas13a Gene-Editing System Induces Collateral Cleavage of RNA in Glioma Cells.

Collateral Effects: The CRISPR‐Cas13a Gene‐Editing System Induces Collateral Cleavage of RNA in Glioma Cells (Adv. Sci. 20/2019)

Universal theranostic CRISPR/Cas13a RNA-editing system for glioma

Collateral cleavage of 28s rRNA by RfxCas13d causes death of mice

Collateral Activity of the CRISPR/RfxCas13d System in Human Cells.

The Collateral Activity of RfxCas13d Can Induce Lethality in a RfxCas13d Knock-in Mouse Model

Genome Editing for Cancer Therapy: Delivery of Cas9 Protein/sgRNA Plasmid Via a Gold Nanocluster/Lipid Core-Shell Nanocarrier

The CRISPR/Cas9 System Targeting EGFR Exon 17 Abrogates NF-κB Activation Via Epigenetic Modulation of UBXN1 in EGFRwt/vIII Glioma Cells

Blood-brain barrier–penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy

The Bacterial Enzyme Cas13 Interferes with Neurite Outgrowth from Cultured Cortical Neurons

Precise RNA Editing: Cascade Self‐Uncloaking Dual‐Prodrug Nanoassemblies Based on CRISPR/Cas13a for Pleiotropic Immunotherapy of PD‐L1‐Resistant Colorectal Cancer

Selective Targeting of the Oncogenic KRAS G12S Mutant Allele by CRISPR/Cas9 Induces Efficient Tumor Regression

Progresses, Challenges, and Prospects of CRISPR/Cas9 Gene-Editing in Glioma Studies

Supramolecular Nanosubstrate‐Mediated Delivery for CRISPR/Cas9 Gene Disruption and Deletion

Lipid Nanoparticle-Mediated Efficient Delivery of CRISPR/Cas9 for Tumor Therapy

Characterisation of RNA editing and gene therapy with a compact CRISPR-Cas13 in the retina

RNA lipid nanoparticles as efficient in vivo CRISPR-Cas9 gene editing tool for therapeutic target validation in glioblastoma cancer stem cells

The Application of CRISPR-Cas System in Glioblastoma Research and Treatment

CRISPR-Cas13: Pioneering RNA Editing for Nucleic Acid Therapeutics

In Vitro Prostate Cancer Treatment via CRISPR-Cas9 Gene Editing Facilitated by Polyethyleneimine-Derived Graphene Quantum Dots

Optimizing a CRISPR-Cas13d Gene Circuit for Tunable Target RNA Downregulation with Minimal Collateral RNA Cutting